ConferenceJCO Clin Cancer Inform · October 2025
PURPOSE: Goals-of-care (GOC) discussions during advanced serious illness and end-of-life (EOL) care are critical. Institutions are increasingly tracking the frequency and timing of GOC documentation, but large-scale content assessments have been limited. W ...
Full textLink to itemCite
ConferenceAnn Surg Oncol · February 2025
BACKGROUND: Hepatic arterial infusion (HAI) is an established treatment for patients with unresectable colorectal liver metastases (uCRLM). Until recently, HAI was only performed at a limited number of centers. We previously reported early outcomes suggest ...
Full textLink to itemCite
ConferenceCancer · January 1, 2025
BACKGROUND: Recipients of radiation therapy (RT) for head and neck cancer (HNC) are at significantly increased risk for carotid artery stenosis (CAS) and cerebrovascular disease (CVD). We sought to determine (1) cumulative incidences of CAS and CVD among H ...
Full textLink to itemCite
ConferenceJournal of Clinical Oncology · June 1, 2024
2668Background: Peritoneal surface malignancies (PSM) constitute a group of difficult-to-treat metastatic diseases that respond poorly to standard chemotherapy. Talimogene Laherparepvec (T-VEC), the first FDA-approved oncolytic virus (OV), demonstrates pot ...
Full textCite
ConferenceJournal of Clinical Oncology · January 1, 2024
Background: Locally advanced esophagogastric adenocarcinoma (EGA) is commonly treated with neoadjuvant chemoradiation (CRT) prior to surgical resection. Adjuvant immunotherapy has been shown to improve outcomes for these patients. The primary objective of ...
Full textCite
ConferenceClin Transplant · August 2023
Despite the increased risk of non-adherence, allograft rejection, and mortality following transfer from pediatric to adult care in liver transplantation (LT), there is no standardized approach to health care transition (HCT). Two electronic national survey ...
Full textLink to itemCite
ConferenceDig Dis Sci · January 2023
BACKGROUND: Acute gastrointestinal (GI) bleeding is one of the leading causes of emergency department visits and hospital admissions. CT angiography (CTA) has had an expanding role in the evaluation of acute GI bleeding because it is rapidly performed, wid ...
Full textLink to itemCite
ConferenceInternational journal of radiation oncology, biology, physics · November 2021
Purpose/objective(s)Mortality prediction is critical to appropriate cancer care planning. This has become a topic of interest, with machine learning (ML) tools demonstrating accurate binary predictions for mortality at specific time points. There ...
Full textCite
ConferenceInternational journal of radiation oncology, biology, physics · November 2021
Purpose/objective(s)Stereotactic body radiation therapy (SBRT) is an established treatment option for stage I non-small cell lung cancer. SBRT often causes acute inflammatory changes in the lung as well as chronic fibrosis. These radiologic findin ...
Full textCite
ConferenceInternational journal of radiation oncology, biology, physics · November 2021
Purpose/objective(s)Radiation is increasingly used to treat oligometastatic patients (OM). Following metastasis directed radiation therapy, progression in nearby nodal basins or bones is common. We previously reported clinical outcomes of OM treat ...
Full textCite
ConferenceInternational journal of radiation oncology, biology, physics · November 2021
Purpose/objective(s)Post-operative radiotherapy (PORT) is utilized in select prostate cancer patients. IMRT has been associated with improved dosimetry and acute toxicity. Smaller treatment margins for PORT have been recommended when using image g ...
Full textCite
ConferenceInternational journal of radiation oncology, biology, physics · November 2021
Purpose/objective(s)Patients undergoing radiotherapy during the COVID-19 pandemic have experienced unique changes to care, including increased use of telehealth for radiotherapy on-treatment visits (OTVs). The objective of this study was to determ ...
Full textCite
ConferenceInternational journal of radiation oncology, biology, physics · November 2021
Purpose/objective(s)Management of HCC without surgical resection or transplantation is poorly defined with no standard. Stereotactic body radiation therapy (SBRT) or hypofractionated image-guided radiotherapy (HIGRT), is an evolving, non-invasive, ...
Full textCite
ConferenceInternational journal of radiation oncology, biology, physics · November 2021
Purpose/objective(s)To date there is no clear standard non-surgical therapeutic option for HCC patients. Ablative radiation therapy (SBRT/HIGRT) is an emerging non-invasive treatment for patients with HCC. However, there is concern about the risk ...
Full textCite
ConferenceLiver Transpl · September 2020
The aim of this study is to validate a proposed definition of sarcopenia in predicting wait-list mortality. We retrospectively evaluated 355 adults (age โฅ18 years) with cirrhosis listed for first-time LT from January 1, 2010, to April 1, 2018 from our cent ...
Full textLink to itemCite
ConferenceDis Esophagus · December 13, 2019
Gastroesophageal reflux and esophageal dysmotility are common in patients with advanced lung disease and are associated with allograft dysfunction after lung transplantation. The effect of transplantation on reflux and esophageal motility is unclear. The a ...
Full textLink to itemCite
ConferenceAmerican Journal of Gastroenterology · October 2019
INTRODUCTION:Patients with alcoholic hepatitis suffer from high rates of malnutrition and are at risk for hypophosphatemia due to poor dietary intake, renal wasting, and r ...
Full textCite
ConferenceCancer Chemother Pharmacol · June 2019
PURPOSE: This study was conducted to define the maximum tolerated dose (MTD), recommended phase two dose (RPTD), and toxicities of gemcitabineโ+โdasatinib (GD) and gemcitabineโ+โdasatinibโ+โcetuximab (GDC) in advanced solid tumor patients. METHODS: This st ...
Full textLink to itemCite
ConferenceJournal of Clinical Oncology · May 20, 2019
4005 Background: Patients (pts) with progressive advanced well-differentiated neuroendocrine tumors arising outside of the pancreas have limited systemic treatment options. Pazopanib (PZ) is an oral multi-kinase inhibitor with ac ...
Full textCite
ConferenceJournal of Clinical Oncology · May 20, 2019
3035 Background: Energy balance-associated biomarkers such as insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) have been associated with risk and prognosis of various malignancies. Their relationship to diseas ...
Full textCite
ConferenceJournal of Clinical Oncology · February 1, 2018
638 Background: Colorectal cancer (CRC) is a heterogeneous disease with distinct molecular subtypes in part based on RAS mutational status. It is plausible that RAS mutations are differentially distributed between CC and AA and m ...
Full textCite
ConferenceJournal of Clinical Oncology · February 1, 2018
TPS873 Background: Initial treatment of metastatic colorectal cancer (mCRC) involves a 5-fluorouracil based chemotherapy regimen, often in combination with anti-VEGF therapy. Upon disease progression, multiple studies have sugges ...
Full textCite
ConferenceBiol Blood Marrow Transplant · November 2017
Treatment-related mortality (TRM) remains elevated in adult patients undergoing umbilical cord blood transplantation (UCBT), including an early rise in TRM suggestive of excessive toxicity associated with the standard myeloablative total body irradiation ( ...
Full textLink to itemCite
ConferenceJournal of Clinical Oncology · June 20, 2017
LBA1 Background: Since 2004, 6 months (m) of oxaliplatin (oxali)-based treatment has been the standard of care as adjuvant therapy for stage III CC. Since oxali is associated with cumulative neurotoxicity, shorter duration of adj ...
Full textCite
ConferenceJournal of Clinical Oncology · May 20, 2017
10006 Background: The ACS Nutrition and Physical Activity Guidelines for Cancer Survivors include: 1) healthy body weight; 2) physical activity; and 3) a diet high in vegetables, fruits, and whole grains. It is not known whether ...
Full textCite
ConferenceJournal of Clinical Oncology · May 20, 2017
TPS3624 Background: To improve survival for patients with mCRC, efforts are needed to identify and treat actionable genomic alterations. HER2 is amplified in approximately 5-8% of patients with KRAS and NRAS (RAS) wild-type mCRC. ...
Full textCite
ConferenceJournal of Clinical Oncology · May 20, 2017
3511 Background: CALGB 80405 was a randomized Ph3 trial showing no OS or PFS difference in mCRC pts treated with Bevacizumab (BV) or Cetuximab (Cet) in the first line. A Nanostring platform was used to determine the CMS classific ...
Full textCite
ConferenceJournal of Clinical Oncology · May 20, 2017
3504 Background: CALGB 80405 was a randomized phase III trial that found no difference in OS in first-line mCRC pts treated with either bevacizumab (Bev) or cetuximab (Cet). Primary tumor DNA from 361 pts, including KRAS mutant ( ...
Full textCite
ConferenceJournal of Clinical Oncology · May 20, 2017
LBA1 The full, final text of this abstract will be available at abstracts.asco.org at 7:30 AM (EDT) on Sunday, June 4, 2017, and in the Annual Meeting Proceedings online supplement to the June 20, 2017, issue of the Journal of Cl ...
Full textCite
ConferenceJournal of Clinical Oncology · May 20, 2017
3528 Background: CALGB 80405 is a phase III clinical trial of FOLFOX and FOLFIRI w/ randomly assigned cetuximab or bevacizumab. Novel machine learning approaches to the study dataset provide valuable insights into CRC prognosis a ...
Full textCite
ConferenceJournal of Clinical Oncology · February 1, 2017
1 Background: To determine whether changing chemotherapy (CT) during pre-op chemoradiation (CRT) based on response to induction CT by 18F-fluoro-deoxyglucose PET imaging can lead to improved pathologic comple ...
Full textCite
ConferenceJournal of Clinical Oncology · February 1, 2017
659 Background: Regular physical activity (PA) is associated with reduced risk of recurrence and mortality in non-metastatic colorectal cancer. Its influence on patients with metastatic colorectal cancer (mCRC) is largely unexplo ...
Full textCite
ConferenceJournal of Clinical Oncology · February 1, 2017
585 Background: Long-chain omega-3 fatty acids (LCN-3 FA) may prevent colon cancer (CC) progression, but data in humans are lacking. We hypothesized that LCN-3 FA and dark meat fish intake after CC diagnosis would be associated w ...
Full textCite
ConferenceJournal of Clinical Oncology · February 1, 2016
687 Background: Patients (pts) with chemotherapy refractory mCRC have a poor prognosis, with a median survival of approximately 6 months (mos). Ziv-aflibercept is FDA-approved in combination with FOLFIRI for the 2nd
Full textCite
ConferenceJournal of Clinical Oncology · January 20, 2015
507 Background: Prospective epidemiologic data suggest that higher levels of 25-hydroxyvitamin D [25(OH)D] are associated with improved survival in patients with colorectal cancer (CRC), however, the relationship between 25(OH)D ...
Full textCite
ConferenceJournal of Clinical Oncology · January 20, 2014
448 Background: Previously, we identified potential predictive biomarkers of C sensitivity related to EGFR signaling from archived tumor tissue from CALGB 80203. Due to the fact that blood-based markers are more convenient and ca ...
Full textCite
ConferenceJournal of Clinical Oncology · January 20, 2014
455 Background: Only 15-25% of pts with stage II colon cancer (CC) experience recurrence and conventional staging methods neither allow accurate identification of low (L) and high-risk (H) subgroups nor predict benefit of adjuvan ...
Full textCite
ConferenceJournal of Clinical Oncology · February 1, 2012
452 Background: The p53 tumor suppressor gene is frequently mutated in colorectal cancer, but reports on the effect of p53 mutations on response to adjuvant chemotherapy and survival are inconclusive. This study investigates whet ...
Full textCite
ConferenceBlood · November 16, 2006
AbstractWe evaluated the feasibility, safety, and effectiveness of an intense IC regimen including ASCT in pts with untreated MCL up to age 70. The primary end-point was 2-year progression free survival (PFS ...
Full textCite
ConferenceBlood · November 16, 2006
AbstractUnrelated umbilical cord blood transplantation (UCBT) is a suitable option for those who lack HLA-matched sibling donors. However, opportunistic infections (OI), with the majority detected in the fir ...
Full textCite
ConferenceBlood · November 16, 2005
AbstractTo minimize toxicity and monitor immune recovery without interference of long term use of immunosuppressive agents, we have investigated T-cell depleted, nonmyeloablative allogeneic therapy using mat ...
Full textCite
ConferenceBlood · November 16, 2004
AbstractTopoisomerase enzymes are critical components of genomic replication and function to minimize torsional stress on DNA. Inhibition of topoisomerase function leads to DNA strand breaks followed by apop ...
Full textCite
ConferenceBlood · November 16, 2004
AbstractIntroduction: Though response may occur with standard therapy, early relapse is common with advanced stage MCL, suggesting the importance of drug resistance in this disease process.It appears that re ...
Full textCite
ConferenceBlood · November 16, 2004
AbstractWe evaluated the feasibility, safety, and effectiveness of an intense IC regimen including ASCT in pts with untreated MCL up to age 70. Pts with MCL confirmed by central pathology review plus one add ...
Full textCite
ConferenceBlood · November 16, 2004
AbstractHLA-mismatched unrelated umbilical cord blood transplantation (uUCBT) is a suitable option for those who lack HLA-matched sibling donors. Although UCB T cells mount significantly less cytotoxicity an ...
Full textCite